| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3879 |
| Trial ID | NCT06414135 |
| Disease | Systemic Sclerosis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Axi-Cel|Relma-cel|Axicabtagene Ciloleucel|JWCAR029|relmacabtagene autoleucel|Yescarta |
| Location approved | China |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Dose Ranging Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Relmacabtagene Autoleucel (Relma-cel) in Patients With Refractory/Progressive Systemic Sclerosis |
| Year | 2024 |
| Country | China |
| Company sponsor | Liangjing Lu |
| Other ID(s) | JWCAR029029 |
| Cohort 1 | |||||||||||
|
|||||||||||